# MightyTIL

Source: https://onco.cc/drugs/mightytil/  
OnCo record `mightytil` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MightyTIL is an experimental cell treatment from TrAMPoline Pharma that strengthens immune cells taken from a patient's own tumour. It is in laboratory testing.

## Summary

MightyTIL is the lead candidate of TrAMPoline Pharma, an autologous gene-engineered TIL product for sarcoma, head and neck cancer and melanoma. The company reports higher potency, persistence and lower IL-2 needs than unmodified TIL in preclinical studies. No clinical data exist.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Also known as: MightyTIL (TrAMPoline Pharma)
- Tags: pipeline
- Modality: Gene-engineered tumour-infiltrating lymphocyte therapy
- Mechanism: Tumour-infiltrating lymphocytes engineered with coR8:Amp, which the developer says strengthens T cell receptor binding to cancer cells and T cell receptor signalling.

## Sources

- TrAMPoline Pharma: https://www.trampolinepharma.com/

## Connected records

- technologies: [TIL therapy](https://onco.cc/technologies/til-therapy/)
- companies: [TrAMPoline Pharma](https://onco.cc/companies/trampoline-pharma/)

---
JSON: https://onco.cc/api/v1/entities/mightytil.json